{"ticker": {"uuid": "96585100-5e98-49f2-871c-60c80f76fd10", "symbol": "TGTX", "name": "TG Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of TG Therapeutics, Inc. (TGTX) breached their fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms for the company. Long-term ", "url": "https://pluang.com/en/news-feed/kuehn-law-ajukan-gugatan-terhadap-tg-therapeutics", "source_name": "Pluang", "published_at": "2026-07-17T02:11:03", "published_display": "17 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Did BRIUMVI\u2019s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative?", "summary": "TG Therapeutics (TGTX) has initiated a Phase 2 trial for its drug BRIUMVI in treatment-resistant schizophrenia, expanding its potential use beyond multiple sclerosis. While this broadens the company's therapeutic footprint, the article suggests it doesn't significantly alter TG's", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/did-briumvis-phase-2-schizophrenia-trial-just-shift-tg-thera", "source_name": "Simply Wall Street", "published_at": "2026-07-16T19:41:53", "published_display": "16 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)", "summary": "Analysts have provided conflicting ratings for Biogen (BIIB) and TG Therapeutics (TGTX) within the Healthcare sector. Argus Research maintained a Hold rating on Biogen with an 11.3% upside price target, while Jefferies reaffirmed a Buy rating for TG Therapeutics, despite a minor ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TGTX-Q/pressreleases/3297421/analysts-conflicted-on-these-healthcare-names-biogen-biib-and-tg-therapeutics-tgtx/", "source_name": "The Globe and Mail", "published_at": "2026-07-16T12:11:03", "published_display": "16 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch", "summary": "TG Therapeutics (TGTX) shares rose after Bank of America analyst Alec Stranahan increased his price target to $20 from $17, despite maintaining an 'Underperform' rating. This comes as the company initiated a mid-stage study for its key drug, Briumvi, in patients with treatment-re", "url": "https://stocktwits.com/news-articles/markets/equity/tgtx-stock-rises-on-wall-street-price-target-hike-new-schizophrenia-trial-launch/cZmlHmHR7ZZ", "source_name": "Stocktwits", "published_at": "2026-07-16T11:13:03", "published_display": "16 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright", "summary": "H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TG Therapeutics (TGTX) with a price target of $77.00. The company reported strong quarterly revenues of $204.92 million and a net profit of $19.78 million for the quarter ending March 31, significantly up from the pr", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TGTX/pressreleases/3274739/tg-therapeutics-tgtx-gets-a-buy-from-hc-wainwright/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T23:44:27", "published_display": "14 Jul 2026 23:44", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNdVBDNnhELWdPSzZEWEVSWi1sN2F4T3JMUWlVZXVic1JCTWROXzYyenluemloSkM1dkhESTFOemdlekFRMTNxeUgwWDd5Ykk5bGZ4V2NMeW0wZEFBMVFHZFJFcUNMb0lQVUsyLUluTk5NUDRLQ0M1cTIxcnA0dkgxR3E4YllqMEx3eHhQMks2NHdwVl9QMUE?oc=5", "source_name": "Market source", "published_at": "2026-07-13T13:47:38+00:00", "published_display": "13 Jul 2026 13:47", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch?", "summary": "TG Therapeutics (TGTX) has garnered attention after initiating a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, expanding beyond multiple sclerosis. Despite a significant share price increase of over 90% year-to-date, analysts estimate the stock is currently over", "url": "https://www.sahmcapital.com/news/content/is-tg-therapeutics-tgtx-fully-valued-following-its-new-schizophrenia-trial-launch-2026-07-12", "source_name": "Sahm", "published_at": "2026-07-12T23:41:53", "published_display": "12 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in TG Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that invest in TG Therapeutics, Inc. (1TGTX) stocks, providing data such as market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, and 3-year NAV total return. The ETFs cover a range of investment strategies, ", "url": "https://www.tradingview.com/symbols/MIL-1TGTX/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T10:09:55", "published_display": "09 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte and TG Therapeutics Deliver Notable Growth, Drawing Investment Attention to the Biotech Sector", "summary": "Incyte and TG Therapeutics are showcasing significant growth in the biotech sector, attracting investor interest. Incyte benefits from a strong product pipeline, robust cash flow, and efficient capital use, while TG Therapeutics is driven by the rapid commercial success of Briumv", "url": "https://nai500.com/blog/2026/07/incyte-and-tg-therapeutics-deliver-notable-growth-drawing-investment-attention-to-the-biotech-sector/", "source_name": "NAI500", "published_at": "2026-07-09T07:47:39", "published_display": "09 Jul 2026 07:47", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial", "summary": "TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2 clinical trial for Briumvi, evaluating its efficacy and safety in adults with treatment-resistant schizophrenia. This follows recent positive Phase 1 data for Briumvi in myasthenia gravis and an increase in Jefferies' price ta", "url": "https://www.insidermonkey.com/blog/tg-therapeutics-tgtx-starts-phase-2-briumvi-trial-1798525/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-09T06:40:00", "published_display": "09 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI\u2019s Role Beyond Multiple Sclerosis?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tg-therapeutics-tgtx-schizophrenia-trial-211530271.html", "source_name": "Simply Wall St.", "published_at": "2026-07-08T21:15:30+00:00", "published_display": "08 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTjZVVDJIalRMcWc5Skpfdk81aG95Y2t2QzdaZEgxU3VSX2hsUU5YdjRGbUdOMllZcHhncTVTbXAyVEhGeHJPdTNhcy1iQmVTbGpUa2tEYkhTaWs5b1JjZ3NPYmgtVGpHOXdOOXJmQy03aTBQM1c1RTZnN3doLXZlSmpGdWc1TlJpOGNrX2trMHJwdWJYSEwwTkJn?oc=5", "source_name": "Market source", "published_at": "2026-07-08T16:17:50+00:00", "published_display": "08 Jul 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia", "summary": "TG Therapeutics (TGTX) has initiated a phase II study for Briumvi (ublituximab-xiiy) to treat adult patients with treatment-resistant schizophrenia, aiming to assess its safety and efficacy in B-cell depletion. Briumvi, already approved for relapsing multiple sclerosis, generated", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TGTX/pressreleases/3164710/tg-therapeutics-begins-phase-ii-study-with-briumvi-in-schizophrenia/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T10:09:55", "published_display": "08 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOa01wUHhFd3J6QWVia3VpWkNGclBQSzZiRTRHM0E3MktUSlR2TkliYmY5VTh5Y1Nrc0U2ckxzTFNGWnhQeTg2WE9NZXdINGJwT1ctUmlERDZNajZMalozOWVTMFNSRDNmMUlzRjV6N3FWVUpENzFqR0dXWnNfY3A4OXVkek5IcHg2VG9qTzhKWFBhV0U4OWVHaE5xMA?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Performing American Stocks in June 2026", "summary": "This article lists the top 5 performing American stocks in June 2026, extracted from a longer list of 10. It details the performance and recent activities of TG Therapeutics, Inc. (NASDAQ:TGTX), including clinical trial initiations and analyst price target updates. The article al", "url": "https://www.insidermonkey.com/blog/5-best-performing-american-stocks-in-june-2026-1797316/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-07T20:50:00", "published_display": "07 Jul 2026 20:50", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-tg-therapeutics-agios-pharmaceuticals-150415176.html", "source_name": "MT Newswires", "published_at": "2026-07-07T15:04:15+00:00", "published_display": "07 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BRIUMVI\u2019s Trial in Treatment-Resistant Schizophrenia Altering The Investment Case For TG Therapeutics (TGTX)?", "summary": "TG Therapeutics has initiated a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, aiming to expand its B-cell-targeting drug beyond multiple sclerosis into a new psychiatric indication. While this scientifically interesting move broadens BRIUMVI's potential, the art", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/is-briumvis-trial-in-treatment-resistant-schizophrenia-alter", "source_name": "Simply Wall Street", "published_at": "2026-07-07T14:11:57", "published_display": "07 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $52.14, Implies 6% Downside", "summary": "Analysts have raised the average 12-month price target for TG Therapeutics, Inc. (TGTX) stock to $52.14, up from $51.71, with individual forecasts ranging from $20 to $83 per share. Despite this increase, the updated target suggests a potential 6% downside based on the July 6 clo", "url": "https://www.tradingview.com/news/tradingview:c2a1496ade2e7:0-tg-therapeutics-inc-stock-12-month-price-target-raised-to-52-14-implies-6-downside/", "source_name": "TradingView", "published_at": "2026-07-07T13:11:57", "published_display": "07 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Announces Initiation of Phase 2 Trial", "summary": "TG Therapeutics has initiated a Phase 2 clinical trial to evaluate BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study aims to determine if B-cell depletion, a mechanism of action for BRIUMVI, can improve symptoms in patients wh", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322333/0/en/TG-Therapeutics-Announces-Initiation-of-Phase-2-Trial-Evaluating-BRIUMVI-in-Patients-with-Treatment-Resistant-Schizophrenia.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T21:11:57", "published_display": "06 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics begins schizophrenia Phase 2 trial", "summary": "TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label, multicenter study of BRIUMVI (ublituximab-xiiy) for treatment-resistant schizophrenia. The trial involves approximately 60 adult participants who will receive BRIUMVI alongside standard antipsychotic therapy. The ", "url": "https://grafa.com/en/news/united-states/tg-therapeutics-briumvi-schizophrenia-phase-2-trial", "source_name": "grafa.com", "published_at": "2026-07-06T13:38:00", "published_display": "06 Jul 2026 13:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Begins Phase 2 Trial of Briumvi in Treatment-Resistant Schizophrenia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tg-therapeutics-begins-phase-2-120431393.html", "source_name": "MT Newswires", "published_at": "2026-07-06T12:04:31+00:00", "published_display": "06 Jul 2026 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia", "summary": "TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label trial to assess the efficacy and safety of BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study will combine intravenous BRIUMVI with standard antipsychotic therap", "url": "https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-initiation-of-phase-2-trial-evaluating-fn5s07yxo4iq.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:42:57", "published_display": "06 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics tests BRIUMVI in 60 schizophrenia patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOOXBJQkRxS1p2dU9ENUsyeGRXdk1XQTlldmtlXzBtSmhFZnNuWEhqTzVBMW1ETTF0N2xnWVl0UjMzN20xMG5IZm1VazI1ajg1MnFKdWszUTlOOVRmaXctUEdLSHUxcXRrYlZKT1ZoQ3lmRHRpRjREQzEtQjNVVWVzWGFUT1ZrT2djZXlfTzd2bFpCRU5HeF93TU1oQm1OOTNSbHRiWDY0UXZtdUpVS3I1QmZ4VzlQOUlPVnFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TGTX - TG Therapeutics Inc Dividends", "summary": "This article provides a detailed financial overview of TG Therapeutics Inc (TGTX), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as P/E, EPS, sales growth, and insider/institutional owner", "url": "https://finviz.com/stock?t=TGTX&ty=dv&p=w", "source_name": "Finviz", "published_at": "2026-07-03T20:09:21", "published_display": "03 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?", "summary": "TG Therapeutics' drug Briumvi has shown strong sales growth, with Q1 2026 sales reaching $201.3 million, and Q2 net sales in the U.S. projected at $220 million. The company faces stiff competition in the multiple sclerosis market from established players like Roche and Novartis, ", "url": "https://sg.finance.yahoo.com/news/briumvis-strength-continue-aid-tgtxs-123100904.html", "source_name": "Market source", "published_at": "2026-07-03T08:31:00", "published_display": "03 Jul 2026 08:31", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of TG Therapeutics, Inc. \u2013 NASDAQ:TGTX", "summary": "This article provides the \"Price to sales forward\" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It lists the period, value, change, and change percentage for this financial indicator. The content is presented as a singular data point within a financial overview for the compan", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:09:07", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TG Therapeutics, Inc. \u2013 MIL:1TGTX", "summary": "This article displays the \"Price to earnings forward\" value for TG Therapeutics, Inc. (MIL:1TGTX). It indicates that the market is currently closed with no trades. The article also provides a list of data providers and copyright notices.", "url": "https://www.tradingview.com/symbols/MIL-1TGTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T20:39:22", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does TG Therapeutics (NASDAQ:TGTX) Deserve A Spot On Your Watchlist?", "summary": "This article evaluates TG Therapeutics' stock (NASDAQ: TGTX) as a potential investment by analyzing its financial health, growth prospects, and valuation. It highlights the company's strong revenue growth, positive shareholder returns over the past year, and relatively low debt. ", "url": "https://www.moomoo.com/news/post/72199894/does-tg-therapeutics-nasdaq-tgtx-deserve-a-spot-on-your", "source_name": "Moomoo", "published_at": "2026-06-29T14:10:20", "published_display": "29 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the TGTX Inflection", "summary": "This article provides an in-depth analysis of Tg Therapeutics Inc. (NASDAQ: TGTX) based on AI models from Stock Traders Daily. It highlights strong near and mid-term sentiment, compelling upside potential due to no resistance levels above current price, and offers three distinct ", "url": "https://news.stocktradersdaily.com/news_release/40/Responsive_Playbooks_and_the_TGTX_Inflection_062926064802_1782730082.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T06:48:00", "published_display": "29 Jun 2026 06:48", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TG Therapeutics, Inc. \u2013 NASDAQ:TGTX", "summary": "This article displays the \"Price to earnings forward\" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It indicates the value and change percentage for a specified period and is presented within the context of TradingView's financial data. The information is sourced from ICE Data", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:39:26", "published_display": "26 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of TG Therapeutics, Inc. \u2013 FWB:NKB2", "summary": "The article provides financial information for TG Therapeutics, Inc. (NKB2) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades recorded at the time of publication. The content al", "url": "https://www.tradingview.com/symbols/FWB-NKB2/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:30", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of TG Therapeutics, Inc. \u2013 NASDAQ:TGTX", "summary": "The article discusses the enterprise value to EBIT forward of TG Therapeutics, Inc. (NASDAQ: TGTX). It presents a financial metric within the context of the company's profile on TradingView, which provides market data and financial tools. The content primarily focuses on the disp", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:30", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious", "summary": "TG Therapeutics (TGTX) has seen significant share price gains recently, prompting a re-evaluation of its valuation. While the most followed narrative suggests the stock is currently 4% overvalued at $51.71, Simply Wall St's DCF model indicates a fair value of $207.76, suggesting ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/tg-therapeutics-tgtx-gains-momentum-as-the-fair-value-narrat", "source_name": "Simply Wall Street", "published_at": "2026-06-25T19:09:30", "published_display": "25 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TGTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for TG Therapeutics, Inc. (TGTX) stock, based on analyst opinions and recent financial performance. It includes current stock price, historical data, earnings reports, revenue figures, and market capitalization, along with frequen", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:30", "published_display": "25 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTdiOFVVRUhqV3B0eHp5M0poaVpxZWszcF9pT0tEQTczYVZaQTA5Wm16d3BsVlk5TWZEd2R3RGdnOWJhQktQcl9JQWtrOUlnRkV5eFdXVE0tOFJXVnk1SHlzVGV6ZjZtZGdXUVYwTVRKc09EcElQaDhMTFlaMm0yYU9xbFV0VXVTUGxsZGF6THNWc01jOEhtRUxxaGszLVV2NmZqNWtBNVF0MVNvdGR5V1VVa1VQS2VQVVh4cXNjTDBkT2lPZEdnTg?oc=5", "source_name": "Trefis", "published_at": "2026-06-23T15:25:21+00:00", "published_display": "23 Jun 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOM3V1aXM2YlBCd3VlVzVNX3dfa09LeEk5YkZ2dVVCUW1rQXFqUW5rbFoxME5CUGVGR2JpT2RwTE44S2w4T0FpUElyNno2V2lSZTIzMmtxdl9Tb3FhV0RyeEZPTTNPbGRIcU5CamZmUGxUZjhObG83X2ptYl82dWlmY21hWmYxaVRqbVVlRHRoS29xSVdESEQtSFhR?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOTVFqb1dJN2NhNm1Lb19WR01FaUJHYUFPYXRna2hCeUE3a2dLS0o3eVZuVXVuSHd6Rmxka0NfN08ydjlwU0tPbTNZVFdtX1p4SjdZVFNWVW10VDRobTZYU0tqdlJrZ09qc0IwMlFUUS1ZNVVjcWlqZk5MVTVUTXhSRUFmUnNLdjJVN0tHMnAwWmo2OFA0anA0Rw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics' BRIUMVI Data Supports Simplified Regimen And Valuation Upside", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMS1TTHFqMWV4anBINGFUWmxNcE93SkFheTRhcmU5cjNkU0hhemVGdDJQWXpUcHc4a3NqY3Q2YTNKM3VsMDZIT0h3MmhfMVdoU0l5azJpLWQyLUlmRjVNOXRmWmpoWkVJcnZ5ZEp0MU41OXAtQkFUUUY2QnVLR3RrR3JHS0VNMTlLWFlvRkJHZXlWZEJ3RGdzUmtJUEpwWFNVS1UtSk9DbXhMcHVkaVE?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOMHhacDdWSzhORTFyTmQzZklYYUlUNHBGZFlQbDlXSlVoOGJHaWV2VDZxQVNwRENRdGpxaHRRZGdQRHNjYkU0SFNGNVJZLTM4Y0dCVk4wU2NZUXRBeXJ4NldkakVNWEhlT2FQVkpTNkVGbm5kUll6ZzFXWFZoa3p5QlAxczA4TXEwSlcxYTlmcnZvRWFkSTluMmYzYUdKM2o2c1E?oc=5", "source_name": "Market source", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has The Market Mispriced TG Therapeutics (TGTX) After Recent Biotech Sector Coverage Swings?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOSnhFUmsxTlRFMHhRa2FTcUFaaHBfV1B4R0JqbklVcXZ2WDBlT2dRcWgtcDk4ZUlMMGxuZlVGY1MtMXBCVXdkSkJRYUxoWFVaREx6UkdQcjBROUozSTFkZlByem9uV0wtRk11cFVmMHFOUTBHaHFVREhrUlhGYWxQM2FSY0hLZHpqNFMtLS1QcWE1ZEY1T1FzU29lelQ3bVpyaWc?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fresh $500M gives TG Therapeutics room to triple stock buybacks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNT3Q5aGdzMFE5VkhHaXB6emtLZHdjT0RtbWFEbE5KN0FaVFJ5TXJscWkzWHIyOTcwcVQxV2RaRnJmSnZ2WFh4REVkWEtndVRPLU1JS3BpMDJib1ByQmlmLU85eDBGallkVFRnQUhLbGZ3b0RPVUFpUGtfalY4QS1hMFdoaGdXSEtTSlh1OWdtOWVGOGRBLWdLRzFvck9OSm90MFZFRC1Yb3lyZ1ZhbXNYX016WkpYM1hWQWZJUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQX2hMeXZWMnk1RVgxNDdNX0hTX0lPRElHbHdDc1JmWGZCd1JkcWRUUFBNcllSV2VpSG1hYmlFSmlweWd6anhvVzUzdkVRQk5VeUVjaDZudDk4cVVxNXNTWEhqZmJUa3Z5V2ZpOVZwMmVGV1NxYmRYRDJLVDVJQnFBNTdBSUZrNEE?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOT0ZUWENtVGZ1c3JESzc5eFE1MFdjVmxBLTUwd2ZzTkszbi1XdUV1NTdOeE00SW9NdWJLS2szbGJmMl8weVZNZkV3WnlXMUg4enFscXZ3ZGlPelNrektvVzM1Z1VTaEtWTjEtT0Y3UVAyTHloTVFadnRlb2RrelhKRw?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPSmI3QTRVNDRBd1d2TWNkQjVuVnlPeE1BcjZvUF83RDJibHFXSkdkVUlhanJUZU1FSTZCaEFOTzNsR05jb19fNUE3SktveENrRWVOWTNiWm96ZG8yLS1ldFRFSGJUcHlESTdIZ2NMaVRtNXEwSHBmZkNaNVNSNGxta194anJXLXplSWRrM21ZZm9ZM2VZYlhtWWZycWk2bGhuQzF6UGlVRXg5U1A1RzJ6ODM1ZlJtS2pIREtoTnZuYzMyNTc5eGdsY1ZKQV93YUNpay1jdXNYRmNTYk9RVWwwWFM2WDEybVk?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of TG Therapeutics, Inc. (TGTX) breached their fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms for the company. Long-term ", "url": "https://pluang.com/en/news-feed/kuehn-law-ajukan-gugatan-terhadap-tg-therapeutics", "source_name": "Pluang", "published_at": "2026-07-17T02:11:03", "published_display": "17 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did BRIUMVI\u2019s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative?", "summary": "TG Therapeutics (TGTX) has initiated a Phase 2 trial for its drug BRIUMVI in treatment-resistant schizophrenia, expanding its potential use beyond multiple sclerosis. While this broadens the company's therapeutic footprint, the article suggests it doesn't significantly alter TG's", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/did-briumvis-phase-2-schizophrenia-trial-just-shift-tg-thera", "source_name": "Simply Wall Street", "published_at": "2026-07-16T19:41:53", "published_display": "16 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)", "summary": "Analysts have provided conflicting ratings for Biogen (BIIB) and TG Therapeutics (TGTX) within the Healthcare sector. Argus Research maintained a Hold rating on Biogen with an 11.3% upside price target, while Jefferies reaffirmed a Buy rating for TG Therapeutics, despite a minor ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TGTX-Q/pressreleases/3297421/analysts-conflicted-on-these-healthcare-names-biogen-biib-and-tg-therapeutics-tgtx/", "source_name": "The Globe and Mail", "published_at": "2026-07-16T12:11:03", "published_display": "16 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch", "summary": "TG Therapeutics (TGTX) shares rose after Bank of America analyst Alec Stranahan increased his price target to $20 from $17, despite maintaining an 'Underperform' rating. This comes as the company initiated a mid-stage study for its key drug, Briumvi, in patients with treatment-re", "url": "https://stocktwits.com/news-articles/markets/equity/tgtx-stock-rises-on-wall-street-price-target-hike-new-schizophrenia-trial-launch/cZmlHmHR7ZZ", "source_name": "Stocktwits", "published_at": "2026-07-16T11:13:03", "published_display": "16 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright", "summary": "H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TG Therapeutics (TGTX) with a price target of $77.00. The company reported strong quarterly revenues of $204.92 million and a net profit of $19.78 million for the quarter ending March 31, significantly up from the pr", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TGTX/pressreleases/3274739/tg-therapeutics-tgtx-gets-a-buy-from-hc-wainwright/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T23:44:27", "published_display": "14 Jul 2026 23:44", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNdVBDNnhELWdPSzZEWEVSWi1sN2F4T3JMUWlVZXVic1JCTWROXzYyenluemloSkM1dkhESTFOemdlekFRMTNxeUgwWDd5Ykk5bGZ4V2NMeW0wZEFBMVFHZFJFcUNMb0lQVUsyLUluTk5NUDRLQ0M1cTIxcnA0dkgxR3E4YllqMEx3eHhQMks2NHdwVl9QMUE?oc=5", "source_name": "Market source", "published_at": "2026-07-13T13:47:38+00:00", "published_display": "13 Jul 2026 13:47", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch?", "summary": "TG Therapeutics (TGTX) has garnered attention after initiating a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, expanding beyond multiple sclerosis. Despite a significant share price increase of over 90% year-to-date, analysts estimate the stock is currently over", "url": "https://www.sahmcapital.com/news/content/is-tg-therapeutics-tgtx-fully-valued-following-its-new-schizophrenia-trial-launch-2026-07-12", "source_name": "Sahm", "published_at": "2026-07-12T23:41:53", "published_display": "12 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in TG Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that invest in TG Therapeutics, Inc. (1TGTX) stocks, providing data such as market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, and 3-year NAV total return. The ETFs cover a range of investment strategies, ", "url": "https://www.tradingview.com/symbols/MIL-1TGTX/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T10:09:55", "published_display": "09 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte and TG Therapeutics Deliver Notable Growth, Drawing Investment Attention to the Biotech Sector", "summary": "Incyte and TG Therapeutics are showcasing significant growth in the biotech sector, attracting investor interest. Incyte benefits from a strong product pipeline, robust cash flow, and efficient capital use, while TG Therapeutics is driven by the rapid commercial success of Briumv", "url": "https://nai500.com/blog/2026/07/incyte-and-tg-therapeutics-deliver-notable-growth-drawing-investment-attention-to-the-biotech-sector/", "source_name": "NAI500", "published_at": "2026-07-09T07:47:39", "published_display": "09 Jul 2026 07:47", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial", "summary": "TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2 clinical trial for Briumvi, evaluating its efficacy and safety in adults with treatment-resistant schizophrenia. This follows recent positive Phase 1 data for Briumvi in myasthenia gravis and an increase in Jefferies' price ta", "url": "https://www.insidermonkey.com/blog/tg-therapeutics-tgtx-starts-phase-2-briumvi-trial-1798525/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-09T06:40:00", "published_display": "09 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI\u2019s Role Beyond Multiple Sclerosis?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tg-therapeutics-tgtx-schizophrenia-trial-211530271.html", "source_name": "Simply Wall St.", "published_at": "2026-07-08T21:15:30+00:00", "published_display": "08 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTjZVVDJIalRMcWc5Skpfdk81aG95Y2t2QzdaZEgxU3VSX2hsUU5YdjRGbUdOMllZcHhncTVTbXAyVEhGeHJPdTNhcy1iQmVTbGpUa2tEYkhTaWs5b1JjZ3NPYmgtVGpHOXdOOXJmQy03aTBQM1c1RTZnN3doLXZlSmpGdWc1TlJpOGNrX2trMHJwdWJYSEwwTkJn?oc=5", "source_name": "Market source", "published_at": "2026-07-08T16:17:50+00:00", "published_display": "08 Jul 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia", "summary": "TG Therapeutics (TGTX) has initiated a phase II study for Briumvi (ublituximab-xiiy) to treat adult patients with treatment-resistant schizophrenia, aiming to assess its safety and efficacy in B-cell depletion. Briumvi, already approved for relapsing multiple sclerosis, generated", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TGTX/pressreleases/3164710/tg-therapeutics-begins-phase-ii-study-with-briumvi-in-schizophrenia/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T10:09:55", "published_display": "08 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOa01wUHhFd3J6QWVia3VpWkNGclBQSzZiRTRHM0E3MktUSlR2TkliYmY5VTh5Y1Nrc0U2ckxzTFNGWnhQeTg2WE9NZXdINGJwT1ctUmlERDZNajZMalozOWVTMFNSRDNmMUlzRjV6N3FWVUpENzFqR0dXWnNfY3A4OXVkek5IcHg2VG9qTzhKWFBhV0U4OWVHaE5xMA?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Performing American Stocks in June 2026", "summary": "This article lists the top 5 performing American stocks in June 2026, extracted from a longer list of 10. It details the performance and recent activities of TG Therapeutics, Inc. (NASDAQ:TGTX), including clinical trial initiations and analyst price target updates. The article al", "url": "https://www.insidermonkey.com/blog/5-best-performing-american-stocks-in-june-2026-1797316/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-07T20:50:00", "published_display": "07 Jul 2026 20:50", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-tg-therapeutics-agios-pharmaceuticals-150415176.html", "source_name": "MT Newswires", "published_at": "2026-07-07T15:04:15+00:00", "published_display": "07 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BRIUMVI\u2019s Trial in Treatment-Resistant Schizophrenia Altering The Investment Case For TG Therapeutics (TGTX)?", "summary": "TG Therapeutics has initiated a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, aiming to expand its B-cell-targeting drug beyond multiple sclerosis into a new psychiatric indication. While this scientifically interesting move broadens BRIUMVI's potential, the art", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/is-briumvis-trial-in-treatment-resistant-schizophrenia-alter", "source_name": "Simply Wall Street", "published_at": "2026-07-07T14:11:57", "published_display": "07 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $52.14, Implies 6% Downside", "summary": "Analysts have raised the average 12-month price target for TG Therapeutics, Inc. (TGTX) stock to $52.14, up from $51.71, with individual forecasts ranging from $20 to $83 per share. Despite this increase, the updated target suggests a potential 6% downside based on the July 6 clo", "url": "https://www.tradingview.com/news/tradingview:c2a1496ade2e7:0-tg-therapeutics-inc-stock-12-month-price-target-raised-to-52-14-implies-6-downside/", "source_name": "TradingView", "published_at": "2026-07-07T13:11:57", "published_display": "07 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Announces Initiation of Phase 2 Trial", "summary": "TG Therapeutics has initiated a Phase 2 clinical trial to evaluate BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study aims to determine if B-cell depletion, a mechanism of action for BRIUMVI, can improve symptoms in patients wh", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322333/0/en/TG-Therapeutics-Announces-Initiation-of-Phase-2-Trial-Evaluating-BRIUMVI-in-Patients-with-Treatment-Resistant-Schizophrenia.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T21:11:57", "published_display": "06 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics begins schizophrenia Phase 2 trial", "summary": "TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label, multicenter study of BRIUMVI (ublituximab-xiiy) for treatment-resistant schizophrenia. The trial involves approximately 60 adult participants who will receive BRIUMVI alongside standard antipsychotic therapy. The ", "url": "https://grafa.com/en/news/united-states/tg-therapeutics-briumvi-schizophrenia-phase-2-trial", "source_name": "grafa.com", "published_at": "2026-07-06T13:38:00", "published_display": "06 Jul 2026 13:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Begins Phase 2 Trial of Briumvi in Treatment-Resistant Schizophrenia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tg-therapeutics-begins-phase-2-120431393.html", "source_name": "MT Newswires", "published_at": "2026-07-06T12:04:31+00:00", "published_display": "06 Jul 2026 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia", "summary": "TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label trial to assess the efficacy and safety of BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study will combine intravenous BRIUMVI with standard antipsychotic therap", "url": "https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-initiation-of-phase-2-trial-evaluating-fn5s07yxo4iq.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:42:57", "published_display": "06 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics tests BRIUMVI in 60 schizophrenia patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOOXBJQkRxS1p2dU9ENUsyeGRXdk1XQTlldmtlXzBtSmhFZnNuWEhqTzVBMW1ETTF0N2xnWVl0UjMzN20xMG5IZm1VazI1ajg1MnFKdWszUTlOOVRmaXctUEdLSHUxcXRrYlZKT1ZoQ3lmRHRpRjREQzEtQjNVVWVzWGFUT1ZrT2djZXlfTzd2bFpCRU5HeF93TU1oQm1OOTNSbHRiWDY0UXZtdUpVS3I1QmZ4VzlQOUlPVnFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TGTX - TG Therapeutics Inc Dividends", "summary": "This article provides a detailed financial overview of TG Therapeutics Inc (TGTX), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as P/E, EPS, sales growth, and insider/institutional owner", "url": "https://finviz.com/stock?t=TGTX&ty=dv&p=w", "source_name": "Finviz", "published_at": "2026-07-03T20:09:21", "published_display": "03 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?", "summary": "TG Therapeutics' drug Briumvi has shown strong sales growth, with Q1 2026 sales reaching $201.3 million, and Q2 net sales in the U.S. projected at $220 million. The company faces stiff competition in the multiple sclerosis market from established players like Roche and Novartis, ", "url": "https://sg.finance.yahoo.com/news/briumvis-strength-continue-aid-tgtxs-123100904.html", "source_name": "Market source", "published_at": "2026-07-03T08:31:00", "published_display": "03 Jul 2026 08:31", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of TG Therapeutics, Inc. \u2013 NASDAQ:TGTX", "summary": "This article provides the \"Price to sales forward\" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It lists the period, value, change, and change percentage for this financial indicator. The content is presented as a singular data point within a financial overview for the compan", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:09:07", "published_display": "01 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TG Therapeutics, Inc. \u2013 MIL:1TGTX", "summary": "This article displays the \"Price to earnings forward\" value for TG Therapeutics, Inc. (MIL:1TGTX). It indicates that the market is currently closed with no trades. The article also provides a list of data providers and copyright notices.", "url": "https://www.tradingview.com/symbols/MIL-1TGTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T20:39:22", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does TG Therapeutics (NASDAQ:TGTX) Deserve A Spot On Your Watchlist?", "summary": "This article evaluates TG Therapeutics' stock (NASDAQ: TGTX) as a potential investment by analyzing its financial health, growth prospects, and valuation. It highlights the company's strong revenue growth, positive shareholder returns over the past year, and relatively low debt. ", "url": "https://www.moomoo.com/news/post/72199894/does-tg-therapeutics-nasdaq-tgtx-deserve-a-spot-on-your", "source_name": "Moomoo", "published_at": "2026-06-29T14:10:20", "published_display": "29 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the TGTX Inflection", "summary": "This article provides an in-depth analysis of Tg Therapeutics Inc. (NASDAQ: TGTX) based on AI models from Stock Traders Daily. It highlights strong near and mid-term sentiment, compelling upside potential due to no resistance levels above current price, and offers three distinct ", "url": "https://news.stocktradersdaily.com/news_release/40/Responsive_Playbooks_and_the_TGTX_Inflection_062926064802_1782730082.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T06:48:00", "published_display": "29 Jun 2026 06:48", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TG Therapeutics, Inc. \u2013 NASDAQ:TGTX", "summary": "This article displays the \"Price to earnings forward\" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It indicates the value and change percentage for a specified period and is presented within the context of TradingView's financial data. The information is sourced from ICE Data", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:39:26", "published_display": "26 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of TG Therapeutics, Inc. \u2013 FWB:NKB2", "summary": "The article provides financial information for TG Therapeutics, Inc. (NKB2) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades recorded at the time of publication. The content al", "url": "https://www.tradingview.com/symbols/FWB-NKB2/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:30", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of TG Therapeutics, Inc. \u2013 NASDAQ:TGTX", "summary": "The article discusses the enterprise value to EBIT forward of TG Therapeutics, Inc. (NASDAQ: TGTX). It presents a financial metric within the context of the company's profile on TradingView, which provides market data and financial tools. The content primarily focuses on the disp", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:30", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious", "summary": "TG Therapeutics (TGTX) has seen significant share price gains recently, prompting a re-evaluation of its valuation. While the most followed narrative suggests the stock is currently 4% overvalued at $51.71, Simply Wall St's DCF model indicates a fair value of $207.76, suggesting ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/tg-therapeutics-tgtx-gains-momentum-as-the-fair-value-narrat", "source_name": "Simply Wall Street", "published_at": "2026-06-25T19:09:30", "published_display": "25 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TGTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for TG Therapeutics, Inc. (TGTX) stock, based on analyst opinions and recent financial performance. It includes current stock price, historical data, earnings reports, revenue figures, and market capitalization, along with frequen", "url": "https://www.tradingview.com/symbols/NASDAQ-TGTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:30", "published_display": "25 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTdiOFVVRUhqV3B0eHp5M0poaVpxZWszcF9pT0tEQTczYVZaQTA5Wm16d3BsVlk5TWZEd2R3RGdnOWJhQktQcl9JQWtrOUlnRkV5eFdXVE0tOFJXVnk1SHlzVGV6ZjZtZGdXUVYwTVRKc09EcElQaDhMTFlaMm0yYU9xbFV0VXVTUGxsZGF6THNWc01jOEhtRUxxaGszLVV2NmZqNWtBNVF0MVNvdGR5V1VVa1VQS2VQVVh4cXNjTDBkT2lPZEdnTg?oc=5", "source_name": "Trefis", "published_at": "2026-06-23T15:25:21+00:00", "published_display": "23 Jun 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOM3V1aXM2YlBCd3VlVzVNX3dfa09LeEk5YkZ2dVVCUW1rQXFqUW5rbFoxME5CUGVGR2JpT2RwTE44S2w4T0FpUElyNno2V2lSZTIzMmtxdl9Tb3FhV0RyeEZPTTNPbGRIcU5CamZmUGxUZjhObG83X2ptYl82dWlmY21hWmYxaVRqbVVlRHRoS29xSVdESEQtSFhR?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOTVFqb1dJN2NhNm1Lb19WR01FaUJHYUFPYXRna2hCeUE3a2dLS0o3eVZuVXVuSHd6Rmxka0NfN08ydjlwU0tPbTNZVFdtX1p4SjdZVFNWVW10VDRobTZYU0tqdlJrZ09qc0IwMlFUUS1ZNVVjcWlqZk5MVTVUTXhSRUFmUnNLdjJVN0tHMnAwWmo2OFA0anA0Rw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics' BRIUMVI Data Supports Simplified Regimen And Valuation Upside", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMS1TTHFqMWV4anBINGFUWmxNcE93SkFheTRhcmU5cjNkU0hhemVGdDJQWXpUcHc4a3NqY3Q2YTNKM3VsMDZIT0h3MmhfMVdoU0l5azJpLWQyLUlmRjVNOXRmWmpoWkVJcnZ5ZEp0MU41OXAtQkFUUUY2QnVLR3RrR3JHS0VNMTlLWFlvRkJHZXlWZEJ3RGdzUmtJUEpwWFNVS1UtSk9DbXhMcHVkaVE?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOMHhacDdWSzhORTFyTmQzZklYYUlUNHBGZFlQbDlXSlVoOGJHaWV2VDZxQVNwRENRdGpxaHRRZGdQRHNjYkU0SFNGNVJZLTM4Y0dCVk4wU2NZUXRBeXJ4NldkakVNWEhlT2FQVkpTNkVGbm5kUll6ZzFXWFZoa3p5QlAxczA4TXEwSlcxYTlmcnZvRWFkSTluMmYzYUdKM2o2c1E?oc=5", "source_name": "Market source", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has The Market Mispriced TG Therapeutics (TGTX) After Recent Biotech Sector Coverage Swings?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOSnhFUmsxTlRFMHhRa2FTcUFaaHBfV1B4R0JqbklVcXZ2WDBlT2dRcWgtcDk4ZUlMMGxuZlVGY1MtMXBCVXdkSkJRYUxoWFVaREx6UkdQcjBROUozSTFkZlByem9uV0wtRk11cFVmMHFOUTBHaHFVREhrUlhGYWxQM2FSY0hLZHpqNFMtLS1QcWE1ZEY1T1FzU29lelQ3bVpyaWc?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fresh $500M gives TG Therapeutics room to triple stock buybacks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNT3Q5aGdzMFE5VkhHaXB6emtLZHdjT0RtbWFEbE5KN0FaVFJ5TXJscWkzWHIyOTcwcVQxV2RaRnJmSnZ2WFh4REVkWEtndVRPLU1JS3BpMDJib1ByQmlmLU85eDBGallkVFRnQUhLbGZ3b0RPVUFpUGtfalY4QS1hMFdoaGdXSEtTSlh1OWdtOWVGOGRBLWdLRzFvck9OSm90MFZFRC1Yb3lyZ1ZhbXNYX016WkpYM1hWQWZJUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQX2hMeXZWMnk1RVgxNDdNX0hTX0lPRElHbHdDc1JmWGZCd1JkcWRUUFBNcllSV2VpSG1hYmlFSmlweWd6anhvVzUzdkVRQk5VeUVjaDZudDk4cVVxNXNTWEhqZmJUa3Z5V2ZpOVZwMmVGV1NxYmRYRDJLVDVJQnFBNTdBSUZrNEE?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOT0ZUWENtVGZ1c3JESzc5eFE1MFdjVmxBLTUwd2ZzTkszbi1XdUV1NTdOeE00SW9NdWJLS2szbGJmMl8weVZNZkV3WnlXMUg4enFscXZ3ZGlPelNrektvVzM1Z1VTaEtWTjEtT0Y3UVAyTHloTVFadnRlb2RrelhKRw?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPSmI3QTRVNDRBd1d2TWNkQjVuVnlPeE1BcjZvUF83RDJibHFXSkdkVUlhanJUZU1FSTZCaEFOTzNsR05jb19fNUE3SktveENrRWVOWTNiWm96ZG8yLS1ldFRFSGJUcHlESTdIZ2NMaVRtNXEwSHBmZkNaNVNSNGxta194anJXLXplSWRrM21ZZm9ZM2VZYlhtWWZycWk2bGhuQzF6UGlVRXg5U1A1RzJ6ODM1ZlJtS2pIREtoTnZuYzMyNTc5eGdsY1ZKQV93YUNpay1jdXNYRmNTYk9RVWwwWFM2WDEybVk?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 56, "sentiment_summary": {"positive": 20, "negative": 5, "neutral": 31, "score": 57, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 57.12, "latest_week": "2026-07-10", "one_week_move": 7.1, "four_week_move": 15.3, "twelve_week_move": 61.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.796883, "market_dynamics_buy_signal": false, "relative_strength": 42.142705, "fair_value_gap": 114.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.5792, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.1% over one week, +15.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 17}, {"label": "TradingView", "count": 9}, {"label": "simplywall.st", "count": 5}, {"label": "Simply Wall Street", "count": 3}, {"label": "The Globe and Mail", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "Insider Monkey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.1% over one week, +15.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders"}], "updated_at": "2026-07-17T13:39:44.453443+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}